Patients not on aspirin therapy should be given non enteric- coated aspirin 325 mg as soon as possible be- (Level of Evidence: B) 3. After PCI, aspirin should be continued indefinitely at a dose of 81 mg to 325 mg daily.27,288,371 (Level of Evidence: B) Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e373 4. A loading dose of a P2Y12 receptor inhibitor should be given before the procedure in patients undergoing PCI with stenting.26,293,302,331,372 375 (Level of Evidence:A) Options include: (Level of Evidence: B) or (Level of Evidence: B) or (Level of Evidence: B) 5. In patients with NSTE-ACS and high-risk features (eg, elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to adminis- ter a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time (Level of Evidence: A) 6. In patients receiving a stent (bare-metal stent or drug-eluting stent [DES]) during PCI for NSTE- inhibitor therapy should be given for at Options include: a. (Level of Evidence: B) or b. Prasugrel#: 10 mg daily302 (Level of Evidence: B) or c. Ticagrelor : 90 mg twice daily293 (Level of Evidence: B) Class IIa 1. It is reasonable to choose ticagrelor over clopido- grel for P2Y12 inhibition treatment in patients with NSTE-ACS treated with an early invasive strategy and/or coronary stenting.293,294 (Level of Evidence: B) 2. It is reasonable to choose prasugrel over clopidogrel treatment in patients with NSTE-ACS who undergo PCI who are not at high risk of bleeding (Level of Evidence: B) 3. In patients with NSTE-ACS and high-risk features (eg, elevated troponin) treated with UFH and ad- equately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofi- ban) at the time of PCI.195,383,384 (Level of Evidence: B) 4. 